Drug details
Nivestym (filgrastim-aafi injection)
type of Hematopoietic Growth Factors
Nivestym (filgrastim-aafi) is a leukocyte growth factor indicated to: decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever; reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML); reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT); mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis; and reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚cyclic neutropenia‚or idiopathic neutropenia.
This drug may have the following side effects:
- hives,
- difficulty breathing,
- swelling of your face, lips, tongue, or throat,
- nausea,
- loss of appetite,
- vomiting,
- fever,
- easy bruising,
- pale skin,
- lightheadedness,
- shortness of breath,
- cold hands and feet,
- chills,
- rapid breathing,
- tiredness,
- stomach pain,
- dizziness,
- back pain,
- wheezing,
- sweating,
- unusual tiredness,
- sore throat,
- flu symptoms,
- little or no urination,
- unusual bleeding (nosebleeds, bleeding gums),
- sudden dizziness,
- fast heart rate,
- blood in your urine,
- unusual weakness
- feeling full,
- pain while breathing,
- swelling or puffiness,
- swelling in your face or ankles,
- mouth sores, and
- sudden or severe pain in your left upper stomach spreading up to your shoulder,
The following drugs are related to Nivestym, either as a replacement or used together:
- Erwinaze (asparaginase erwinia chrysanthemi)
- Besponsa (inotuzumab ozogamicin injection)
- Blincyto (blinatumomab for injection)
- Clolar (clofarabine)
- Sprycel (dasatinib)
- Gleevec (imatinib mesylate)
- Iclusig (ponatinib tablets)
- Kymriah (tisagenlecleucel suspension for intravenous infusion)
- Monjuvi (tafasitamab-cxix injection)
- Oncaspar (pegaspargase)